Drugs / VN-0200
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04914520 | Jun → Dec 2021 | respiratory syncytial virus infectious disease | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05547087 | Oct 2022 → Apr 2023 | respiratory syncytial virus infectious disease | Daiichi Sankyo | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VN-0200 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04914520 ↗ |
| Modality | Vaccine | “VN-0200 (antigen: VAGA-9001a, adjuvant: MABH-9002b)” NCT05547087 ↗ |
| Route | Intramuscular | “administered as an intramuscular injection into the deltoid muscle of the upper arm” NCT04914520 ↗ |